361559 Sigma-AldrichGSK-3 Inhibitor XVI - CAS 252917-06-9 - Calbiochem
GSK-3 Inhibitor XVI - CAS 252917-06-9, is a cell-permeable, potent, ATP-competitive, and highly selective GSK-3 inhibitor (IC₅₀ = 10 and 6.7 nM against GSK-3α and GSK-3β, respectively).
More>> GSK-3 Inhibitor XVI - CAS 252917-06-9, is a cell-permeable, potent, ATP-competitive, and highly selective GSK-3 inhibitor (IC₅₀ = 10 and 6.7 nM against GSK-3α and GSK-3β, respectively). Less<<Synonymes: 6-(2-(4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino)ethyl-amino)-nicotinonitrile, CHIR99021
Produits recommandés
Aperçu
| Replacement Information |
|---|
Tableau de caractéristiques principal
| CAS # | Empirical Formula |
|---|---|
| 252917-06-9 | C₂₂H₁₈Cl₂N₈ |
Prix & Disponibilité
| Référence | Disponibilité | Conditionnement | Qté | Prix | Quantité | |
|---|---|---|---|---|---|---|
| 361559-5MG |
|
Ampoule plast. | 5 mg |
|
— |
| Description | |
|---|---|
| Overview | A cell-permeable aminopyrimidine compound that acts as potent, ATP-competitive, and highly selective GSK-3 inhibitor (IC50 = 10 and 6.7 nM against GSK-3α and GSK-3β, respectively). Exhibits little or no activity toward 46 other enzymes (IC50 >8.8 µM against 20 kinases and Ki ≥5 µM against 23 non-kinase enzymes) and shows only weak binding to 22 pharmacologically relevant receptors (Kd ~4 µM). This compound is orally available and is shown to effectively improve glucose metabolism in both murine and rat type 2 diabetes models in vivo. Also available as a 25 mM solution in DMSO (Cat. No. 361571). |
| Catalogue Number | 361559 |
| Brand Family | Calbiochem® |
| Synonyms | 6-(2-(4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino)ethyl-amino)-nicotinonitrile, CHIR99021 |
| Product Information | |
|---|---|
| CAS number | 252917-06-9 |
| Form | White to beige solid |
| Hill Formula | C₂₂H₁₈Cl₂N₈ |
| Chemical formula | C₂₂H₁₈Cl₂N₈ |
| Structure formula Image | |
| Quality Level | MQ200 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Purity | ≥95% by HPLC |
| Physicochemical Information |
|---|
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Référence | GTIN |
| 361559-5MG | 04055977214208 |
Documentation
Required Licenses
| Title |
|---|
| PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD |
GSK-3 Inhibitor XVI - CAS 252917-06-9 - Calbiochem FDS
| Titre |
|---|
GSK-3 Inhibitor XVI - CAS 252917-06-9 - Calbiochem Certificats d'analyse
| Titre | Numéro de lot |
|---|---|
| 361559 |
Références bibliographiques
| Aperçu de la référence bibliographique |
|---|
| Mussmann, R., et al. 2007. J. Biol. Chem. 282, 12030. Ring, D.B., et al. 2003. Diabetes 52, 588. Bennett, C.N., et al. 2002. J. Biol. Chem. 277, 30998. Cline, G.W., et al. 2002. Diabetes 51, 2903. |
Fiche technique
| Titre |
|---|
| Reprogramming Cell Fate and Function Novel Strategies for iPSC Generation, Characterization, and Differentiation |



